Preliminary Study for the Preparation of Transmucosal or Transdermal Patches with Acyclovir and Lidocaine

• Published in: Polymers Vol. 13; no. 20; p. 3596
• Main Authors: Marioane, Cristina-Adela, Bunoiu, Mădălin, Mateescu, Mădălina, Sfîrloagă, Paula, Vlase, Gabriela, Vlase, Titus
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 19.10.2021; MDPI
• Subjects: acyclovir; alginate; Binary mixtures; Bioavailability; Compatibility; Composition; Controlled release; DNA polymerase; Drug delivery systems; Drug dosages; Fourier transforms; FTIR; Herpes viruses; Infections; Infrared analysis; Infrared spectroscopy; Kinases; lidocaine; Membranes; Patches (structures); Pharmaceutical industry; Polyvinyl alcohol; Polyvinylpyrrolidone; PVA; PVP; Sodium alginate; Surfactants; Thermogravimetry; Ulcers; United States > US; Germany
• ISSN: 2073-4360; 2073-4360
• DOI: 10.3390/polym13203596

The present study aimed to prepare and evaluate patches for the controlled release of lidocaine/acyclovir and the binary mixture between lidocaine: acyclovir in the oral cavity. Mucoside adhesive patches containing 12.5 mg/cm2 lidocaine/acyclovir or binary mixture base were developed by a solvent casting method using sodium alginate, polyvinylpyrrolidone (PVP), glycerol (Gly), polyvinyl alcohol (PVA), and Span 80 (S). Binary mixtures between all components were prepared before the patches’ formulation in order to be able to check the substance compatibility. All formulated patches were analyzed by FT-IR spectroscopy, UV-Vis analysis, thermogravimetry (TGA), and scanning electron microscopy (SEM). FT-IR and TGA analyses were also used to check compatibility between binary mixtures. The study establishes which membranes are indicated in the controlled release of lidocaine/acyclovir and those membranes that contain both active principles. Membranes based on alginate, PVP, and PVA can be used to release the active substance. Simultaneously, membranes with SPAN used as a gelling agent were excluded due to the interaction with the active substance. The following membranes composition have been chosen for lidocaine release: Alginate:Gly and Alginate:Gly:PVP. At the same time, the following membrane compositions were chosen for acyclovir membranes: Alginate:Gly:PVP and Alginate:PVA:Gly. Both active substances could be included to obtain a homogeneous distribution only in the membrane based on alginate, PVA, and Gly.